Period:
Draw Mode:
| Volume | 32,958,021 |
|
|||||
| News | - | ||||||
| Day High | 0.74 | Low High |
|||||
| Day Low | 0.57 | ||||||
| Company Name | Stock Ticker Symbol | Market | Type |
|---|---|---|---|
| eFFECTOR Therapeutics Inc | EFTR | NASDAQ | Common Stock |
| Price Change | Change Percent | Stock Price | Last Traded
|
|
|---|---|---|---|---|
| 0.141 | 26.65% | 0.67 | 19:59:47 |
| Open Price | Low Price | High Price | Close Price | Prev Close |
|---|---|---|---|---|
| 0.7151 | 0.57 | 0.74 | 0.66 | 0.529 |
| Trades | Volume | VWAP | Dollar Volume | Avg Volume | 52 Week Range |
|---|---|---|---|---|---|
| 84,328 | 32,958,021 | $ 0.6197689 | $ 20,426,356 | - | 0.3378 - 2.97 |
| Last Trade Time | Type | Quantity | Stock Price | Currency |
|---|---|---|---|---|
| 19:59:47 | formt | 300 | $ 0.67 | USD |
eFFECTOR Therapeutics Inc Financials
| Market Cap | Shares in Issue | Float | Revenue | Profit/Loss | EPS | PE Ratio |
|---|---|---|---|---|---|---|
| $ 28.41M | 42.40M | 42.35M | $ - | $ - | -0.24 | - |
| Short Interest | Dividends Per Share | Dividend Yield | Ex-Div Date | Insider B/S | Insider % Owned |
|---|---|---|---|---|---|
| - | $ - | - | 2.11M | 0.10% |
eFFECTOR Therapeutics News
Loading Messages....
|
|
{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}} |
Loading Messages....
Historical EFTR Price Data
| Period | Open | High | Low | VWAP | Avg. Daily Vol | Change | % |
|---|---|---|---|---|---|---|---|
| 1 Week | 0.675 | 0.79 | 0.4665 | 0.6009779 | 1,106,438 | -0.005 | -0.74% |
| 1 Month | 0.45 | 0.79 | 0.4024 | 0.5927301 | 484,877 | 0.22 | 48.89% |
| 3 Months | 0.5217 | 0.79 | 0.3378 | 0.5192873 | 264,130 | 0.1483 | 28.43% |
| 6 Months | 0.48 | 0.79 | 0.3378 | 0.5212334 | 300,316 | 0.19 | 39.58% |
| 1 Year | 1.77 | 2.97 | 0.3378 | 0.6329258 | 471,963 | -1.10 | -62.15% |
| 3 Years | 19.00 | 40.42 | 0.3378 | 10.23 | 505,456 | -18.33 | -96.47% |
| 5 Years | 19.00 | 40.42 | 0.3378 | 10.23 | 505,456 | -18.33 | -96.47% |
eFFECTOR Therapeutics Description
| eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors (STRIs) for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK1/2 that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer (NSCLC). The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 1/2 clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. The company was founded in 2012 and is headquartered in San Diego, California. |